A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth

Journal of Cellular Physiology

Volumn 230, Issue 10, 2015, Pages 2447-2460

  Peserico, Alessia ^a,b   Germani, Aldo ^a   Sanese, Paola ^a   Barbosa, Armenio Jorge ^c   Di Virgilio, Valeria ^a   Fittipaldi, Raffaella ^d   Fabini, Edoardo ^c   Bertucci, Carlo ^c   Varchi, Greta ^e   Moyer, Mary Pat ^f   Caretti, Giuseppina ^d   Del Rio, Alberto ^c,e   Simone, Cristiano ^a,b  

^a UNIVERSITY OF BARI   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e CNR   (Italy)

^f National Research Council ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCI 121; ENZYME INHIBITOR; HISTONE H3; HISTONE H4; HISTONE LYSINE METHYLTRANSFERASE; LYSINE; MESSENGER RNA; METHYLTRANSFERASE; UNCLASSIFIED DRUG; SMYD3 PROTEIN, HUMAN; SMYD3 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MOLECULAR DOCKING; MOUSE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL TRANSFORMATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; TRANSCRIPTION INITIATION; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; LIVER NEOPLASMS; MICE; RNA INTERFERENCE; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84932620730     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24975     Document Type: Article

References (27)

1. Biggar KK, Li SSC. 2015. Non-histone protein methylation as a regulator of cellular signalling and function. Nat Rev Mol Cell Biol 16:5-17.
2. Chi P, Allis CD, Wang GG. 2010. Covalent histone modifications-miswritten, misinterpreted, and mis-erased in human cancers. Nat Rev Cancer 10:457-469.
3. Chiacchiera F, Matrone A, Ferrari E, Ingravallo G, Lo Sasso, Petruzzelli S, Salvatore M, Moschetta L, Simone A, 2009. P38alpha blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1alpha- to FoxO-dependent transcription. Cell Death Differ 16:1203-1214.
4. Cock-Rada AM, Medjkane S, Janski N, Yousfi N, Perichon M, Chaussepied M, Chluba J, Langsley G, Weitzman JB. 2012. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9. Cancer Res 72:810-820.
5. Copeland RA, Solomon ME, Richon VM. 2009. Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov 8:724-732.
6. De Robertis M, Massi E, Poeta ML, Morini S, Cecchetelli L, Signori E, Fazio VM. 2011. The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J Carcinog 24:10-19.
7. Del Rio A, Barbosa AJM, Caporuscio F, Mangiatordi GF. 2010. CoCoCo: A free suite of multiconformational chemical databases for high-throughput virtual screening purposes. Mol Biosyst 6:2122-2128.
8. Foreman KW, Brown M, Park F, Emtage S, Harriss J, Das C, Zhu L, Crew A, Arnold L, Shaaban S, Tucker P. 2011. Structural and functional profiling of the human histone methyltransferase SMYD3. PLoS One 6:e22290.
9. Gaedcke J, Grade M, Jung K, Camps J, Jo P, Emons G, Gehoff A, Sax U, Schirmer M, Becker H, Beissbarth T, Ried T, Ghadimi BM. 2010. Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes Chromosomes Cancer 49:1024-1034.
10. Greer EL, Shi Y. 2012. Histone methylation: A dynamic mark in health, disease, and inheritance. Nat Rev Genet 13:343-357.
11. Guil S, Soler M, Portela A, Carrère J, Fonalleras E, Gómez A, Villanueva A, Esteller M. 2012. Intronic RNAs mediate EZH2 regulation of epigenetic targets. Nat Struct Mol Biol 19:664-670.
12. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, Yagyu R, Nakamura Y. 2004. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 6:731-740.
13. Hamamoto R, Silva FP, Tsuge M, Nishidate T, Katagiri T, Nakamura Y, Furukawa Y. 2006. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 97:113-118.
14. Helin K, Dhanak D. 2013. Chromatin proteins and modifications as drug targets. Nature 502:480-488.
15. Klein AM, Zaganjor E, Cobb MH. 2013. Chromatin-tethered MAPKs. Curr Opin Cell Biol 25:272-277.
16. Kim H, Heo K, An W. 2009. Requirement of histone methyltransferase SMYD3 for estrogen receptor-mediated transcription. J Biol Chem 284:19867-19877.
17. Kunizaki M, Hamamoto R, Silva FP, Yamaguchi K, Nagayasu T, Shibuya M, Nakamura Y, Furukawa Y. 2007. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3. Cancer Res 67:10759-10765.
18. Liu C, Fang X, Ge Z, Jalink M, Kyo S, Björkholm M, Gruber A, Sjöberg J, Xu D. 2007. The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3. Cancer Res 67:2626-2631.
19. Liu Y, Luo X, Deng J, Pan Y, Zhang L, Liang H. 2014. SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma. Tumour Biol. doi:10.1007/s13277-014-2891-z.
20. Luo XG, Zhang CL, Zhao WW, Liu ZP, Liu L, Mu A, Guo S, Wang N, Zhou H, Zhang TC. 2014. Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells. Cancer Lett 344:129-137.
21. Mazur PK, Reynoird N, Khatri P, Jansen PWTC, Wilkinson AW, Liu S, Barbash O, Van Aller GS, Huddleston M, Dhanak D, Tummino PJ, Kruger RG, Garcia BA, Butte AJ, Vermeulen M, Sage J, Gozani O. 2014. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature 510:283-287.
22. O'Connor PM, Jackman J. 1998. Synchronization of mammalian cells. In: Celis JE, Ed. Cell biology: A Laboratory Handbook. San Diego: Academic Press. pp 63-74.
23. Suganuma T, Workman JL. 2012. MAP kinases and histone modification. J Mol Cell Biol 4:348-350.
24. Tsuge M, Hamamoto R, Silva FP, Ohnishi Y, Chayama K, Kamatani N, Furukawa Y, Nakamura Y. 2005. A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers. Nat Genet 37:1104-1107.
25. Van Aller GS, Reynoird N, Barbash O, Huddleston M, Liu S, Zmoos A, Sinnamon R, Le B Mas, Sage R, Garcia J, Tummino BA, Gozani PJ, Kruger O, 2012. SMYD3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Epigenetics 7:340-343.
26. Varier RA, Timmers HTM. 2011. Histone lysine methylation and demethylation pathways in cancer. Biochim Biophys Acta 1815:75-89.
27. Zou JN, Wang SZ, Yang JS, Luo XG, Xie JH, Xi T. 2009. Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF. Cancer Lett. 280:78-85.